ADX10059

Migraine prevention by targeting glutamate receptors?

...raine patients, significantly more patients taking adx10059 than those taking placebo (16.7% vs 4.7%, respecti... p = 0.039) were pain-free two hours after dosing. adx10059 administration yielded better pain improvement tha... In addition, there were trends to superiority for adx10059 over placebo for migraine pain improvement (mild o...

ADX10059 in Medical Technology

Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease

GENEVA, April 17, 2007 /PRNewswire/ -- Addex Pharmaceuticals announced today the successful completion of a Phase IIa proof of concept trial with its lead compound ADX10059 in patients with gastro-esophageal reflux disease (GERD), a highly prevalent condition with a significant unmet medical need....

Addex Reports Positive Results in Phase IIa Clinical Trial With ADX10059 in Migraine

... IIa proof of concept trial with its lead compound adx10059 in patients with migraine. The study achieved its ...improvement of migraine pain at other time points. adx10059 has already recently demonstrated a potential ther...rrently completing a Phase IIa study in anxiety. adx10059 is a potent, selective, negative allosteric modula...

ADX10059 in other areas

Addex: Better Tolerated Formulation of ADX10059 Reduces Acid Reflux ...

Addex: Better Tolerated Formulation of ADX10059 Reduces Acid Reflux. ... ADX10059 is a first-in-class negative allosteric modulator (NAM) of metabotropic ...

Addex Starts A Second Phase IIb Trial Of ADX10059 In GERD

Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced the start of a Phase IIb trial of ADX10059 monotherapy in patients with ...

Addex Starts A Phase IIb Trial Of ADX10059 For Migraine Prevention

Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced the start of a Phase IIb trial of ADX10059 as a migraine prevention therapy in ...

A proof-of-concept study evaluating the effect of ADX10059, a ...

ADX10059 250 mg tds reduced pH-metry-measured oesophageal acid exposure, ... ADX10059 50 mg tds was not significantly superior to placebo. ADX10059 was ...

A Proof Of Concept Study Evaluating The Effect Of ADX10059, A ...

ADX10059 was generally well tolerated. Conclusion: The mGluR5 NAM ADX10059 ... ADX10059 appears to have a potential role in clinical management of GERD. ...

ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux ...

Evaluation of the effect of ADX10059 on symptom control in patients with ... Drug: ADX10059 Matching Placebo. oral administration. Eligibility. Ages Eligible ...